Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Chen AP, et al. Among authors: takebe n. N Engl J Med. 2023 Sep 7;389(10):911-921. doi: 10.1056/NEJMoa2303383. N Engl J Med. 2023. PMID: 37672694 Free PMC article. Clinical Trial.
The NCI-MATCH trial: lessons for precision oncology.
O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, McShane LM, Patton DR, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Rubinstein LV, Little RF, Arteaga CL, Marinucci D, Hamilton SR, Conley BA, Harris LN, Doroshow JH. O'Dwyer PJ, et al. Among authors: takebe n. Nat Med. 2023 Jun;29(6):1349-1357. doi: 10.1038/s41591-023-02379-4. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322121 Review.
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Emiloju OE, et al. Among authors: takebe n. Invest New Drugs. 2024 Feb;42(1):127-135. doi: 10.1007/s10637-024-01420-8. Epub 2024 Jan 25. Invest New Drugs. 2024. PMID: 38270822 Clinical Trial.
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, Siravegna G, Camphausen K, Chi G, Fetter IJ, Brugge JS, Chen H, Takebe N, Penson RT, Juric D, Flaherty KT, Sullivan RJ, Clark JW, Heist RS, Matulonis UA, Liu JF, Shapiro GI. Corcoran RB, et al. Among authors: takebe n. Clin Cancer Res. 2024 May 1;30(9):1739-1749. doi: 10.1158/1078-0432.CCR-23-3135. Clin Cancer Res. 2024. PMID: 38456660 Free PMC article. Clinical Trial.
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y, Jo U, Kumar S, Sun NY, Elloumi F, Thomas A, Roper N, Varghese DG, Takebe N, Zhang X, Ceribelli M, Holland DO, Beck E, Itkin Z, McKnight C, Wilson KM, Travers J, Klumpp-Thomas C, Thomas CJ, Hoang CD, Hernandez JM, Del Rivero J, Pommier Y. Arakawa Y, et al. Among authors: takebe n. Cancer Res Commun. 2024 Mar 19;4(3):834-848. doi: 10.1158/2767-9764.CRC-24-0085. Cancer Res Commun. 2024. PMID: 38451783 Free PMC article.
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.
Naqash AR, Floudas CS, Aber E, Maoz A, Nassar AH, Adib E, Choucair K, Xiu J, Baca Y, Ricciuti B, Alessi JV, Awad MM, Kim C, Judd J, Raez LE, Lopes G, Nieva JJ, Borghaei H, Takebe N, Ma PC, Halmos B, Kwiatkowski DJ, Liu SV, Mamdani H. Naqash AR, et al. Among authors: takebe n. JCO Precis Oncol. 2024 Feb;8:e2300371. doi: 10.1200/PO.23.00371. JCO Precis Oncol. 2024. PMID: 38330261
Blood-based multi-cancer detection: A state-of-the-art update.
Farooq M, Leevan E, Ahmed J, Ko B, Shin S, De Souza A, Takebe N. Farooq M, et al. Among authors: takebe n. Curr Probl Cancer. 2024 Feb;48:101059. doi: 10.1016/j.currproblcancer.2023.101059. Epub 2024 Jan 5. Curr Probl Cancer. 2024. PMID: 38181630 Review.
Association of plasminogen activator inhibitor-1 and fibroblastic growth factor 21 in 3 groups of type 2 diabetes: Without overweight/obesity, free of insulin resistance, and without hepatosteatosis.
Takebe N, Hasegawa Y, Matsushita Y, Chiba H, Onodera K, Kinno H, Oda T, Nagasawa K, Segawa T, Takahashi Y, Okada K, Ishigaki Y. Takebe N, et al. Medicine (Baltimore). 2023 Sep 1;102(35):e34797. doi: 10.1097/MD.0000000000034797. Medicine (Baltimore). 2023. PMID: 37657012 Free PMC article.
177 results